Characteristics of study participants
| Characteristic . | All participants . | HIT-positive participants . |
|---|---|---|
| Number of participants, n | 526 | 32 |
| Age, years (SD) | 66.5 (15.4) | 68.6 (12.9) |
| Sex, M/F | 271/256 | 15/17 |
| Heparin exposure, n (%) | ||
| UFH | 330 (63) | 18 (56) |
| LMWH | 81 (15) | 3 (9) |
| Both | 105 (20) | 11 (34) |
| Unclear | 10 (2) | 0 |
| Patient type,*n (%) | ||
| Cardiovascular surgery | 121 (23) | 11 (32) |
| Noncardiovascular surgery | 121 (23) | 7 (20) |
| Medicine | 253 (48) | 4 (12) |
| Oncology | 69 (13) | 5 (16) |
| Critical care (ICU/CCU) | 269 (51) | 5 (16) |
| Indication for anticoagulation,*n (%) | ||
| Treatment of VTE | 114 (22) | 5 (16) |
| Cardiac valve/vascular surgery | 39 (7) | 10 (29) |
| Treatment of ischemic heart disease | 43 (8) | 0 |
| Stroke prevention in context of atrial fibrillation | 55 (10) | 0 |
| Thromboprophylaxis | 276 (52) | 17 (53) |
| Characteristic . | All participants . | HIT-positive participants . |
|---|---|---|
| Number of participants, n | 526 | 32 |
| Age, years (SD) | 66.5 (15.4) | 68.6 (12.9) |
| Sex, M/F | 271/256 | 15/17 |
| Heparin exposure, n (%) | ||
| UFH | 330 (63) | 18 (56) |
| LMWH | 81 (15) | 3 (9) |
| Both | 105 (20) | 11 (34) |
| Unclear | 10 (2) | 0 |
| Patient type,*n (%) | ||
| Cardiovascular surgery | 121 (23) | 11 (32) |
| Noncardiovascular surgery | 121 (23) | 7 (20) |
| Medicine | 253 (48) | 4 (12) |
| Oncology | 69 (13) | 5 (16) |
| Critical care (ICU/CCU) | 269 (51) | 5 (16) |
| Indication for anticoagulation,*n (%) | ||
| Treatment of VTE | 114 (22) | 5 (16) |
| Cardiac valve/vascular surgery | 39 (7) | 10 (29) |
| Treatment of ischemic heart disease | 43 (8) | 0 |
| Stroke prevention in context of atrial fibrillation | 55 (10) | 0 |
| Thromboprophylaxis | 276 (52) | 17 (53) |
CCU, cardiac care unit; ICU, intensive care unit; SD, standard deviation; UFH, unfractionated heparin; VTE, venous thromboembolism.
Categories not mutually exclusive.